

1 **Comparison of haemoglobin concentration measurements using HemoCue-301 and**
2 **Sysmex XN-Series 1500: a survey among anaemic Gambian infants aged 6-12 months**

3

4 Mamadou Bah, MSc^{1,2}, Hans Verhoef, PhD², Abdou Camara¹, SEN, Morris Nden Ngom¹,
5 SEN, Demba Jallow¹, SEN, Kebba Bajo¹, Foday Bah¹, Maarten Pleij² BSc, Maaïke Klappe²
6 BSc, Alasana Saidykhan¹, BSc, Emmanuel Okoh, MBBS, MPH¹, Abdoulie Bah, BSc¹, Carla
7 Cerami, MD, PhD^{1*}

8

9 *¹Medical Research Council (MRC) Unit The Gambia at London School of Hygiene & Tropical*
10 *Medicine (LSHTM), PO Box 273, Fajara, The Gambia*

11 *²Division of Human Nutrition and Health, Wageningen University, PO Box 17, 6700 AA*
12 *Wageningen, The Netherlands*

13 **Correspondence to: Dr Carla Cerami at the MRC Unit The Gambia @ LSHTM, Atlantic*
14 *Boulevard, Fajara, Banjul, The Gambia Email: carla.cerami@lshtm.ac.uk; Tel: +220-*
15 *7875756*

16 **ABSTRACT**

17 **Background & Aims:** In low-income countries, point-of-care photometers are used in the
18 screening and management of anaemia in individuals, but also in the assessment of
19 population iron status when evaluating efficacy of intervention studies or public health
20 interventions. We aimed to evaluate the accuracy of a commonly used photometer,
21 HemoCue-301, in determining haemoglobin concentration among anaemic children aged 6-
22 12 months in a field setting in rural Africa.

23 **Methods:** This report concerns a secondary analysis of data from Gambian infants being
24 screened for an ongoing randomized controlled trial. In those found to be anaemic by
25 HemoCue-301, haemoglobin concentration was measured by Sysmex XN-1500, an
26 automated haematology analyser that was used as a reference. Passing-Bablok regression
27 analysis was used to estimate the regression constant (systematic deviation between two
28 measurement methods that remain consistent across the range of measurements) and
29 proportional bias (systematic deviation between two measurement methods that change in
30 magnitude relative to the value being measured).

31 **Results:** Analysis was based on 227 participants. There was strong evidence of absolute
32 bias among moderately anaemic participants (haemoglobin concentration at 8.0g/dL)
33 (absolute bias: 1.12g/dL; 95% CI: 0.91 to 1.37g/dL; proportional bias: 14.0%; 95% CI: 11.4%
34 to 17.1%) in haemoglobin concentrations measured by HemoCue-301 compared to those
35 measured by Sysmex XN-Series1500. Bias was marginal at haemoglobin concentration of
36 11.0g/dL (absolute bias: -0.08g/dL; 95% CI: -0.18 to 0.07g/dL; proportional bias: -7.3%; 95%
37 CI: -6.5% to 0.6%).

38 **Conclusion:** Haemoglobin measurements by HemoCue-301 seem substantially biased in
39 participants with haemoglobin less than 8.0g/dL.

40 **Key words:** Diagnostic techniques, haematologic; haemoglobin, anaemia; point-of-care
41 systems; child; Gambia

42 1. INTRODUCTION

43 Accurate measurement of haemoglobin concentrations is important in the screening and
44 management of anaemia in individuals, but also in the assessment of population iron status
45 in surveys to evaluate the efficacy of intervention studies or public health interventions.
46 Automated haematology analysers are generally considered the reference standard. These
47 analysers are expensive and require specific ambient temperatures, cold storage for
48 reagents, and a stable source of electricity, which poses challenges in field settings (1). To
49 address these challenges, various battery-operated point-of-care photometers have been
50 introduced. They rely on either pooled or single capillary blood samples, making them
51 convenient for use in field settings and are widely used for country-wide anaemia prevalence
52 studies (2).

53

54 One such photometer is the HemoCue-301 (HemoCue, Ängelholm, Sweden), which was
55 specifically developed to withstand challenging environments and does not utilise any
56 hygroscopic ingredients (3). The HemoCue-301 utilises a double-wavelength method,
57 measuring the absorbance of whole blood at 506nm the Hb/HbO₂ isosbestic point (i.e., the
58 wavelength where Hb and HbO₂ have the same absorbance or intensity), and at a
59 wavelength of 880nm to compensate for turbidity. However, this technique is sensitive to
60 oxygen, resulting in a 1.3% increase in measured haemoglobin concentration per minute
61 the sample is left in open air (4). Therefore, readings must be completed within 20-30
62 seconds to ensure accuracy (3).

63

64 Despite their benefits, variability in haemoglobin measurements between these point-of-care
65 devices and automated haematology analysers has been reported (5). A systematic review
66 of 8 studies revealed higher haemoglobin concentration measurements of capillary blood
67 using HemoCue-301 compared to measurement of venous blood in automated haematology

68 analysers (4), with differences ranging from 0.5 to 6.1 g/L (4). However, most of these
69 studies determined the difference in haemoglobin measurement between the techniques
70 using Bland-Altman analysis (6–14). Unlike Bland-Altman analysis, Passing-Bablok
71 regression analysis is a non-parametric method that does not assume constant
72 measurement errors between methods and is robust against outliers (15).

73

74 We aimed to evaluate the accuracy of the HemoCue-301 in determining haemoglobin
75 concentration among anaemic children aged 6-12 months in a field setting in rural Africa. As
76 a reference, we used the Sysmex XN-1500 (Sysmex Corporation, Kobe, Japan), an
77 automated haematology analyser that utilises a cyanide-free sodium lauryl sulphate reagent
78 to lyse red blood cells, which, once released, forms a stable-coloured complex that is then
79 measured photometrically (16).

80

81 **2. Materials & Methods**

82 This study contains an analysis of baseline data obtained from an ongoing efficacy trial of
83 haem iron versus ferrous sulphate in infants aged 6-12 months (17). The trial received
84 ethical approval from the Scientific Coordinating Committee of the Medical Research
85 Council (MRC) Unit The Gambia, the Joint Gambia Government MRC Ethics Committee,
86 and the Ethics Committee at the London School of Hygiene and Tropical Medicine
87 (LEO27648) and adheres to the principles of Good Clinical Practice, with oversight from a
88 Data Safety and Monitoring Board, and will be subject to monitoring by the Clinical Trials
89 Office at the MRCG@LSHTM. The trial is registered with the Pan African Clinical Trial
90 Registry (PACTR202210523178727) at www.pactr.org.

91

92 **2.1 Sample collection**

93 Enrolment of participants started on the 11th of May 2023 in Jara West and Kiang East of
94 The Gambian and concluded on the 1st of November 2023. Potential participants were
95 recruited from vaccination clinics or in their respective communities. After obtaining consent
96 from parents/guardians, capillary blood samples were collected in the field by a trained
97 nurse. While seated, the participant's finger was cleaned, and non-fasting blood was
98 collected by pricking the thumb with a lancet (Microtainer Contact-Activated Lancet, Becton-
99 Dickinson, Franklin Lakes, NJ, USA). The initial capillary droplet was removed, and the
100 second droplet was used to fill the microcuvette, ensuring that no air bubbles were
101 introduced. Any excess blood on the sides of the microcuvette was wiped, and haemoglobin
102 concentration was measured immediately by inserting the microcuvette into the HemoCue-
103 301 photometer. Children with anaemia (haemoglobin <11.0g/dL by HemoCue-301) were
104 invited for further screening and haemoglobin assessment was repeated using the reference
105 method. For each participant, a 0.5mL venous blood sample was collected by a nurse into
106 K₂EDTA tubes (BD microtainer, reference number 365975), and samples were kept
107 between 4°C–8°C until transferred to a central laboratory, where haemoglobin concentration
108 was assessed within 4 hours of initial blood draw using a Sysmex XN-1500 analyser. Study
109 data were collected and managed using REDCap electronic data capture tools hosted at
110 MRC Unit The Gambia (18).

111

112 **2.2 Quality control**

113 The HemoCue-301 is factory-calibrated against international reference samples and no
114 further calibration is possible by the end user (19). Weekly quality control checks were done
115 for the HemoCue-301 utilising the control blood samples purchased for use with the Sysmex
116 machine (XN Check, L1 catalogue number; 213484, L2 catalogue number; 213485, L3
117 catalogue number; 213486). No quality control failures were noted during the trial. The
118 Sysmex XN-Series 1500 (Sysmex Corporation, Japan) instrument is housed in an

119 accredited Good Clinical Laboratory Practice (GCLP) laboratory at MRCG at LSHTM at the
120 Keneba field station. Daily quality checks and controls were conducted. All sample analyses
121 were carried out by a trained scientific officer to ensure the accuracy and reliability of the
122 data throughout the study.

123

124 **2.3 Statistical analysis**

125 The statistical analysis was conducted in RStudio version 3.0. Passing-Bablok regression,
126 a non-parametric method, was used to determine potential absolute and proportional bias
127 using the Method Comparison Regression (mcr) package. Bias refers to non-random errors
128 between measurements obtained from two different methods. Proportional bias refers to a
129 systematic error in which the magnitude of the bias is directly proportional to the true value
130 of the variable being measured. Unlike traditional linear regression, the Passing-Bablok
131 regression method is insensitive to outliers and does not assume normal distribution,
132 constant variance, or a linear relationship (15). We defined absolute and proportional bias
133 when the confidence intervals excluded 0 and 1 for the intercept or the slope respectively.
134 A difference of $\pm 7\%$ between methods as recommended by the College of American
135 Pathologists and the Westgard Clinical Laboratory Improvement Amendments was
136 considered acceptable (20).

137

138 **3. RESULTS**

139 A total of 227 participants had their haemoglobin assessed using both the HemoCue-301
140 and Sysmex XN-Series 1500 and were included in the analysis. The participants had a mean
141 age of 7.5 months (SD: 1.6 months); 52% were female. Of 227 participants identified as
142 anaemic according to the HemoCue-301, 17 were found to be not anaemic using the
143 Sysmex haematology analyser. One participant was classified as severely anaemic

144 (haemoglobin <7.0 g/dl) according to the Sysmex haematology analyser but not the
145 HemoCue-301.

146

147 The median haemoglobin concentrations for HemoCue-301 and Sysmex XN-Series were
148 10.2 g/dL (IQR: 9.8, 10.7 g/dL) and 9.8 g/dL (IQR:9.2, 10.4 g/dL), respectively. For severe
149 anaemia (haemoglobin concentration at 6.5 g/dL), Hemocue measurements showed an
150 absolute bias of 1.72 g/dL (95% CI: 1.37 to 2.10 g/dL) and a proportional bias of 26.5% (95%
151 CI: 21.1% to 32.3%). Moderate anaemia (haemoglobin concentration at 8.0 g/dL) showed
152 an absolute bias of 1.12 g/dL (95% CI: 0.91 to 1.37 g/dL) and a proportional bias of 14.0%
153 (95% CI: 11.4% to 17.1%), while mild anaemia cases (haemoglobin concentration <10.0
154 g/dL) showed an absolute bias of 0.32 g/dL (95% CI: 0.26 to 0.42 g/dL) and a proportional
155 bias of 3.2% (95% CI: 2.6% to 4.2%). Bias was marginal at haemoglobin concentration of
156 11.0 g/dL (absolute bias: -0.08 g/dL; 95% CI: -0.18 to 0.07; proportional bias: -7.3%; 95%
157 CI: -6.5 to 0.6). A modest positive correlation coefficient of 0.31, as indicated by Kendall's
158 tau, indicates limited agreement between the measurement methods.

159

160 **4. DISCUSSION**

161 We demonstrated that haemoglobin measurements between HemoCue-301 and the
162 Sysmex XN-1500 vary across different haemoglobin concentrations and the magnitude of
163 bias is inversely proportional to haemoglobin concentration. There was strong evidence of
164 a absolute bias in haemoglobin concentrations above the acceptable difference of $\pm 7\%$ set
165 by the College of American Pathologists and Westgard Clinical Laboratory Improvement
166 Amendments in moderate and severely anaemic participants (20).

167

168 The diagnostic accuracy of HemoCue-301 compared to automated hematology analyzers
169 has been examined in several studies. While some studies have reported acceptable

170 differences within $\pm 7\%$, others have shown higher difference(4,21). Our study indicated that
171 HemoCue-301 measurements were 26.5% higher than the Sysmex values at a hemoglobin
172 concentration of 6.5 g/dL with an absolute bias of 1.72 g/dL much higher than the acceptable
173 $\pm 7\%$. Among participants with a hemoglobin concentration of 8.0 g/dL, 14.0% showed an
174 absolute bias of 1.12 g/dL, while those with a hemoglobin concentration of 11.0 g/dL showed
175 marginal or non-existent bias. Similarly, a study conducted in Laotian children reported a
176 higher bias in anaemic compared to non-anaemic children (22). In blood donors, no bias
177 was observed at a haemoglobin concentration of 12.0 g/dl when compared to the WHO
178 reference standard haemoglobin-cyanide technique (11). A systematic review of 8 studies
179 among adults indicated higher HemoCue-301 haemoglobin concentration measurements
180 compared to automated analysers. This study concluded that the difference fell within the
181 acceptable limit of $\pm 7\%$ set by the College of American Pathologists and Westgard Clinical
182 Laboratory Improvement Amendments (4). However, it is important to acknowledge that
183 differences in haemoglobin measurements vary between methods at different
184 concentrations, as demonstrated by our study, which was not accounted for in this study.

185

186 The HemoCue-301 operates on spectrophotometric principles, where the absorbance of
187 light passing through a blood sample is directly proportional to the concentration of
188 haemoglobin at the Hb/HbO₂ isosbestic point. Due to the stringent adherence to the
189 haemoglobin measurement protocol within our clinical trial, the observed higher
190 haemoglobin concentrations, particularly in anaemic children, are likely attributable to device
191 bias arising from increased absorbance at lower haemoglobin concentrations rather than
192 preanalytical errors. In contrast, a study among women in Peru has indicated lower
193 haemoglobin concentrations measured by HemoCue-301 compared to automated
194 analysers, with 50% of these women classified as anaemic according to HemoCue-301 (23).
195 However, in our analysis, only 7.4% of participants were misclassified as anaemic by the

196 HemoCue-301, while they were classified as normal (haemoglobin concentrations greater
197 than 11 g/dL) according to the Sysmex XN-1500.

198

199 According to WHO guidelines, paediatric blood transfusion should be performed on patients
200 with haemoglobin less than 4.0 g/dl with clinical signs of severity (24). However, few facilities
201 in sub-Saharan countries have access to reliable haemoglobin tests with a turnaround time
202 between 1 and 8 hours [5] As a result, around 40-65% of requested transfusions are based
203 on clinical judgment, such as severe pallor (5). This clinical judgment is often inaccurate in
204 identifying severe anaemia (haemoglobin less than 5.0 g/dl), leading to unnecessary
205 transfusions (25,26). This does not only expose children to transfusion-related risks but may
206 also contribute to blood scarcity for patients who are most in need (26,27). Therefore, the
207 ability to provide rapid diagnosis of severe anaemia is critical for life-saving interventions
208 and the prioritisation of blood units for those in most need. A study conducted in Kenya,
209 Tanzania, and Uganda revealed that a delay in blood transfusion for severely anaemic
210 children within the first 8 hours resulted in a 52% mortality rate, with 90% of these deaths
211 occurring within the initial 2.5 hours(28). This outcome was associated with insufficient blood
212 units, emphasising the importance of managing and prioritising the already scarce blood
213 resources to prevent avoidable deaths (28). Conversely, in a Kenyan hospital, children
214 receiving transfusion on the same day, compared to the following day, were associated with
215 a 42% reduction in mortality (29). In the TRACT trial, where participants aged between 2 to
216 12 months were randomised to either immediate or triggered transfusion, active hemoglobin
217 measurement by the HemoCue-301 method in the control group resulted in 49.0% of
218 children receiving timely transfusions. Additionally, there was evidence of lower mortality,
219 perhaps due to the active hemoglobin monitoring every 8 hours in the first 24 hours and at
220 48 hours (30). However, our study showed that this method tends to overestimate

221 hemoglobin concentration, particularly in participants with moderate to severe anaemia,
222 potentially resulting in children who require a blood transfusion not receiving it.

223

224 The WHO is currently involved in ongoing research to comprehensively understand
225 preanalytical and analytical factors influencing haemoglobin measurement using these
226 point-of-care devices. This research aims to inform the development of new guidelines in
227 this area (31) and our study will contribute to the existing evidence that can be utilised in
228 these guidelines' development. This study is part of an ongoing clinical trial, thus ensuring
229 stringent monitoring and adherence to trial protocols throughout the blood sampling process
230 and haemoglobin measurements. This study has several limitations as it was a secondary
231 data analysis using a convenience sampling method. Consequently, the findings may not
232 be generalisable to rural Gambian children aged between 6 and 12 months. Additionally,
233 capillary and venous blood sampling for haemoglobin measurement were not performed on
234 the same day. The retrospective nature of our study limited our ability to explore the potential
235 impact of different blood sample types (venous vs capillary) on haemoglobin concentration
236 measurements. Furthermore, our study design did not allow for a direct comparison between
237 point-of-care tests and automated haematology analysers regarding anaemia prevalence.
238 This is because only children identified as anaemic by HemoCue-301 underwent
239 haemoglobin measurements using the automated analyser.

240

241 **5. Conclusion**

242 Our study indicated that bias due to HemoCue-301 depends on the actual Hb concentration,
243 and seems unacceptably high at Hb values below 8.0 g/dL. While this method may offer
244 convenience in field surveys for estimating anaemia prevalence, caution is required when
245 using it for a screen-and-treat approach.

246

247

248 **Declarations**

249 *Acknowledgements*

250 We thank the IDeA3 study team at MRCG@LSHTM for their dedicated support, the MRCG
251 Keneba laboratory, the data management team and the MRCG Clinical Trial Unit. We also
252 thank the participants and communities of Kiang East and Jarra West.

253

254 *Authors' contributions*

255 MB conceived this paper, and contributed to the analysis, writing of the original paper,
256 reviewing, and editing and coordinated the study as part of his PhD, overseeing all aspects
257 of study implementation. CC conceived the overall trial idea and acquisition of funding, and
258 design and is the overall principal investigator, contributed to the writing of the paper,
259 reviewing, editing and supervising MB. HV contributed to the study design, sample size
260 calculation and statistical analysis plan, writing of the paper, reviewing, and editing and co-
261 supervised MB. AMP contributed to the study idea, design, writing of the paper, reviewing,
262 and editing. EO is the research clinician on the trial contributed to data collection and
263 reviewed and edited the paper. AC, MNG, DJ, KB, AS, MK, and MP contributed to data
264 collection reviewing and editing of the paper. AB is the data manager and contributed to the
265 reviewing and editing of the paper.

266

267 *Funding*

268 This study was funded by a grant from the UK Research & Innovation (UKRI) to the Medical
269 Research Council Unit The Gambia at London School of Hygiene & Tropical Medicine (grant
270 reference: MR/R023360/1). CC, AMP, EO, AB, AC, MNG, DJ, KB and AS are funded
271 through MRCG@LSHTM. MB is partially funded through MRCG@LSHTM, Wageningen
272 University and MR/R023360/1. HV, MK, and MP are funded by Wageningen University.

273

274 *Role of the funding source*

275 The funder had no role in the design or implementation of the study.

276

277 *Competing interests*

278 There is no competing interest to disclose.

279

280 *Authors and Affiliations*

281 Mr. Mamadou Bah (PhD Candidate and Sub-Investigator, Affiliation: MRC Unit The Gambia
282 @ LSHTM & Wageningen University, Division of Human Nutrition and Health, The
283 Netherlands)

284 Dr. Carla Cerami (Principal Investigator and Research Group Lead: Iron, Infection and
285 Anaemia; Affiliation: MRC Unit The Gambia @ LSHTM Research Group)

286 Prof. Andrew M Prentice (Sub-Investigator, Nutrition and Planetary Health Theme Leader;
287 Affiliation: MRC Unit The Gambia @ LSHTM)

288 Dr. Hans Verhoef (Sub-Investigator and Trial Statistician, Affiliation: Wageningen University,
289 Division of Human Nutrition and Health, The Netherlands)

290 Dr Emmanuel Okoh (Research Clinician: MRC Unit The Gambia @ LSHTM Research
291 Group)

292 Abdoulie Bah, (Data support assistant: MRC Unit The Gambia @ LSHTM Research Group)

293 Alasana Saidu Khan, (Scientific Officer: MRC Unit The Gambia @ LSHTM Research Group)

294 Abdou Camara, (Nurse Coordinator: MRC Unit The Gambia @ LSHTM Research Group)

295 Kebba Bajo, (Field Coordinator: MRC Unit The Gambia @ LSHTM Research Group)

296 Morris Ndene Ngom, (Research Nurse: MRC Unit The Gambia @ LSHTM Research Group)

297 Demba Jallow, (Research Nurse: MRC Unit The Gambia @ LSHTM Research Group)

298 Foday Bah, (Field Supervisor: MRC Unit The Gambia @ LSHTM Research Group)

299 Maaïke Klappe (MSc student, Affiliation: Wageningen University, Division of Human
300 Nutrition and Health, The Netherlands)

301 Maarten Pleij (MSc student, Affiliation: Wageningen University, Division of Human Nutrition
302 and Health, The Netherlands)

303

304

305

306 References

307

- 308 1. Garcia-Casal MN, Dary O, Jefferds ME, Pasricha SR. Diagnosing anemia:
309 Challenges selecting methods, addressing underlying causes, and implementing
310 actions at the public health level. *Ann N Y Acad Sci* [Internet]. 2023 Jun 1 [cited
311 2023 Nov 21];1524(1):37–50. Available from:
312 <https://onlinelibrary.wiley.com/doi/full/10.1111/nyas.14996>
313
- 314 2. Srivastava T, Negandhi H, Neogi SB, Sharma J, Saxena R. Methods for Hemoglobin
315 Estimation: A Review of "What Works. *J Hematol Transfus*. 2014;2(3):1028.
316
- 317 3. HemoCue. HemoCue® Hb 301. 2024.
318
- 319 4. Whitehead RD, Mei Z, Mapango C, Jefferds MED. Methods and analyzers for
320 hemoglobin measurement in clinical laboratories and field settings. *Ann N Y Acad*
321 *Sci* [Internet]. 2019 [cited 2024 Jan 30];1450(1):147. Available from:
322 </pmc/articles/PMC6709845/>
323
- 324 5. Uyoga S, George EC, Bates I, Olupot-Olupot P, Chimalizeni Y, Molyneux EM, et al.
325 Point-of-care haemoglobin testing in African hospitals: a neglected essential
326 diagnostic test. [cited 2023 Nov 21]; Available from:
327 www.ekfdiagnostics.com/diaspect.html
328
- 329 6. Jaggernath M, Naicker R, Madurai S, Brockman MA, Ndung'u T, Gelderblom HC.
330 Diagnostic Accuracy of the HemoCue Hb 301, STAT-Site MHgb and URIT-12 Point-
331 of-Care Hemoglobin Meters in a Central Laboratory and a Community Based Clinic
332 in Durban, South Africa. *PLoS One* [Internet]. 2016 Apr 1 [cited 2023 Nov 21];11(4).
333 Available from: <https://pubmed.ncbi.nlm.nih.gov/27046200/>
334
- 335 7. Lardi AM, Hirst C, Mortimer AJ, McCollum CN. Evaluation of the HemoCue® for
336 measuring intra-operative haemoglobin concentrations: A comparison with the
337 Coulter Max-M®. *Anaesthesia*. 1998;53(4):349–52.
338
- 339 8. Rechner IJ, Twigg A, Davies AF, Imong S. Evaluation of the HemoCue compared
340 with the Coulter STKS for measurement of neonatal haemoglobin. *Arch Dis Child*
341 *Fetal Neonatal Ed*. 2002;86(3).
342
- 343 9. Karakochuk CD, Janmohamed A, Whitfield KC, Barr SI, Vercauteren SM, Kroeun H,
344 et al. Evaluation of two methods to measure hemoglobin concentration among
345 women with genetic hemoglobin disorders in Cambodia: A method-comparison
346 study. *Clinica Chimica Acta*. 2015 Feb 20;441:148–55.
347
- 348 10. Morris SS, Ruel MT, Cohen RJ, Dewey KG, De La Brière B, Hassan MN. Precision,
349 accuracy, and reliability of hemoglobin assessment with use of capillary blood. *Am J*
350 *Clin Nutr*. 1999 Jun 1;69(6):1243–8.
351
- 352 11. Morris LD, Osei-Bimpong A, McKeown D, Roper D, Lewis SM. Evaluation of the
353 utility of the HemoCue 301 haemoglobinometer for blood donor screening. *Vox*
354 *Sang*. 2007 Jul;93(1):64–9.
355

- 356 12. Karakochuk CD, Hess SY, Moorthy D, Namaste S, Parker ME, Rappaport AI, et al.
357 Measurement and interpretation of hemoglobin concentration in clinical and field
358 settings: a narrative review. *Ann N Y Acad Sci* [Internet]. 2019 Aug 1 [cited 2023
359 Dec 4];1450(1):126–46. Available from:
360 <https://onlinelibrary.wiley.com/doi/full/10.1111/nyas.14003>
361
- 362 13. Getaneh Z, Woldu B, Sitotaw C, Melku M. Comparison of hemoglobin levels by
363 HemoCue301+ and Sysmex KX-21N at University of Gondar Hospital, Northwest
364 Ethiopia, 2020. *Clin Lab* [Internet]. 2022 [cited 2023 Dec 4];68(11):2316–24.
365 Available from: <https://pubmed.ncbi.nlm.nih.gov/36378003/>
366
- 367 14. Jain A, Chowdhury N. Comparison of the accuracy of capillary hemoglobin
368 estimation and venous hemoglobin estimation by two models of HemoCue against
369 automated cell counter hemoglobin measurement. *Asian J Transfus Sci* [Internet].
370 2020 Jan 1 [cited 2023 Dec 4];14(1):49. Available from: </pmc/articles/PMC7607980/>
371
- 372 15. Bilić-Zulle L. Comparison of methods: Passing and Bablok regression. *Biochem Med*
373 (Zagreb) [Internet]. 2011 [cited 2023 Dec 5];21(1):49–52. Available from:
374 <https://pubmed.ncbi.nlm.nih.gov/22141206/>
375
- 376 16. Hill VL, Simpson VZ, Higgins JM, Hu Z, Stevens RA, Metcalf JA, et al. Evaluation of
377 the Performance of the Sysmex XT-2000i Hematology Analyzer With Whole Bloods
378 Stored at Room Temperature. *Lab Med* [Internet]. 2009 Dec [cited 2024 Jan
379 30];40(12):709. Available from: </pmc/articles/PMC2860627/>
380
- 381 17. Bah M, Verhoef H, Okoh E, Prentice A, Cerami C. Haem iron versus ferrous iron
382 salts to treat iron deficiency anaemia in Gambian children: protocol for randomised
383 controlled trial {1}. 2024;
384
- 385 18. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research
386 Electronic Data Capture (REDCap) - A metadata-driven methodology and workflow
387 process for providing translational research informatics support. *J Biomed Inform*
388 [Internet]. 2009 Apr [cited 2024 Mar 8];42(2):377. Available from:
389 </pmc/articles/PMC2700030/>
390
- 391 19. HemoCue. Hb 301 System | Robust Blood Testing Set | HemoCue America
392 [Internet]. 2023 [cited 2023 Dec 14]. Available from: <https://www.hemocue.us/hb-301/>
393
394
- 395 20. WestgardQC. CLIA Requirements for Analytical Quality - Westgard [Internet]. 2023
396 [cited 2024 Apr 16]. Available from: <https://www.westgard.com/clia-a-quality/quality-requirements/125-clia.html>
397
398
- 399 21. Fothergill A, Crider KS, Johnson CB, Raj MP, Guetterman HM, Bose B, et al.
400 Comparison of Anemia Screening Methods Using Paired Venous Samples in
401 Women of Reproductive Age in Southern India. *J Nutr* [Internet]. 2022 Dec 1 [cited
402 2024 Apr 16];152(12):2978. Available from: </pmc/articles/PMC9840000/>
403
- 404 22. Hinnouho GM, Barffour MA, Wessells KR, Brown KH, Kounnavong S,
405 Chanhthavong B, et al. Comparison of haemoglobin assessments by HemoCue and
406 two automated haematology analysers in young Laotian children. *J Clin Pathol*


- 407 [Internet]. 2018 [cited 2023 Nov 21];71(6):532. Available from:
408 /pmc/articles/PMC5969348/
409
- 410 23. Alarcón-Yaquetto DE, Rueda-Torres L, Bailon N, Barreto PV, Málaga G. Accuracy of
411 HemoCue301 portable hemoglobin analyzer for anemia screening in capillary blood
412 from women of reproductive age in a deprived region of Northern Peru: An on-field
413 study. PLoS One [Internet]. 2023 Oct 25 [cited 2024 Mar 8];18(11). Available from:
414 /pmc/articles/PMC10645325/
415
- 416 24. WHO. Guidelines for the management of common childhood illnesses; Pocket book
417 of Hospital Care for Children [Internet]. 2nd Edition. 2013 [cited 2023 Nov 28]. 1–438
418 p. Available from: <https://www.who.int/publications/i/item/978-92-4-154837-3>
419
- 420 25. Olupot-Olupot P, Prevatt N, Engoru C, Nteziyaremye J, Amorut D, Chebet M, et al.
421 Open Peer Review Evaluation of the diagnostic accuracy and cost of different
422 methods for the assessment of severe anaemia in hospitalised children in Eastern
423 Uganda [version 2; referees: 3 approved]. 2019 [cited 2023 Dec 5]; Available from:
424 <https://doi.org/10.12688/wellcomeopenres.14801.1>
425
- 426 26. Brehm R, South A, George EC. Use of point-of-care haemoglobin tests to diagnose
427 childhood anaemia in low- and middle-income countries: A systematic review.
428 Tropical Medicine & International Health [Internet]. 2023 [cited 2023 Dec 14];
429 Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/tmi.13957>
430
- 431 27. Opoka RO, Ssemata AS, Oyang W, Nambuya H, John CC, Tumwine JK, et al. High
432 rate of inappropriate blood transfusions in the management of children with severe
433 anemia in Ugandan hospitals. BMC Health Serv Res [Internet]. 2018 Jul 18 [cited
434 2023 Dec 5];18(1):1–9. Available from:
435 <https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-018-3382-5>
436
- 437 28. Kiguli S, Maitland K, George EC, Olupot-Olupot P, Opoka RO, Engoru C, et al.
438 Anaemia and blood transfusion in African children presenting to hospital with severe
439 febrile illness. 2015 [cited 2023 Dec 5]; Available from:
440 <http://dx.doi.org/10.1186/s12916-014-0248-5>.
441
- 442 29. Thomas J, Ayieko P, Ogero M, Gachau S, Makone B, Nyachiro W, et al. Blood
443 Transfusion Delay and Outcome in County Hospitals in Kenya. Am J Trop Med Hyg
444 [Internet]. 2017 Feb 2 [cited 2023 Dec 5];96(2):511. Available from:
445 /pmc/articles/PMC5303061/
446
- 447 30. Maitland K, Kiguli S, Olupot-Olupot P, Engoru C, Mellewa M, Goncalves PS, et al.
448 Transfusion in African Children with Uncomplicated Severe Anemia. N Engl J Med
449 [Internet]. 2019 Aug 8 [cited 2023 Dec 4];381(5):407. Available from:
450 /pmc/articles/PMC7611152/
451
- 452 31. WHO. Call for authors - Developing a systematic review on accuracy and precision
453 of data collection and analytical methods for haemoglobin assessment in
454 populations [Internet]. 2023 [cited 2023 Dec 7]. Available from:
455 [https://www.who.int/news-room/articles-detail/call-for-authors-developing-a-](https://www.who.int/news-room/articles-detail/call-for-authors-developing-a-systematic-review-on-accuracy-and-precision-of-data-collection-and-analytical-methods-for-haemoglobin-assessment-in-populations)
456 [systematic-review-on-accuracy-and-precision-of-data-collection-and-analytical-](https://www.who.int/news-room/articles-detail/call-for-authors-developing-a-systematic-review-on-accuracy-and-precision-of-data-collection-and-analytical-methods-for-haemoglobin-assessment-in-populations)
457 [methods-for-haemoglobin-assessment-in-populations](https://www.who.int/news-room/articles-detail/call-for-authors-developing-a-systematic-review-on-accuracy-and-precision-of-data-collection-and-analytical-methods-for-haemoglobin-assessment-in-populations)
458

460 **Table 1:** Presents the absolute and proportional bias with their corresponding 95%
461 confidence intervals, for haemoglobin concentration measurements obtained by
462 HemoCue-301. The absolute bias is expressed in grams per decilitre (g/dL), and the
463 proportional bias is presented as a percentage (%).

Aneamia Category	Sysmex Haemoglobin; g/dL	Absolute bias; g/dL (95% CI)	Proportional Bias; % (95% CI)
Severe	6.5	1.72 (1.37 to 2.10)	26.5 (21.1 to 32.3)
Moderate	8.0	1.12 (0.91 to 1.37)	14.0 (11.4 to 17.1)
Mild	10.0	0.32 (0.26 to 0.42)	3.2 (2.6 to 4.2)
normal	11.0	-0.08 (-0.18 to 0.07)	-7.3 (-6.5 to 0.6)

464

465
466
467
468



469
470

Figure 1 Comparison of haemoglobin concentrations measured by HemoCue 301 vs Sysmex XN-1500.

471 HemoCue data were truncated at haemoglobin concentration <11.0g/dL (see text)

472 **Panel A:** The black line represents the Passing-Bablok equation: *HaemoCue Haemoglobin*
473 $= Intercept (4.32) + Slope(0.60) \times Sysmex Haemoglobin$; the red dashed line
474 represents the identity line; the grey shade area indicates the 95% confidence band.

475 **Panel B:** The black line represents the Passing-Bablok equation: *Absolute Bias* =
476 $HemoCue method(Intercept + Slope \times Sysmex Haemoglobin) -$
477 $(Sysmex Haemoglobin(reference method))$; the red line signifies the zero bias, the blue
478 dashed line represent $\pm 7\%$ acceptable difference and the grey shade indicates the 95%
479 confidence interval.

480 **Panel C:** The black line represents the Passing-Bablok equation: *Proportional bias*(X_c) =
481 $\frac{Intercept + (Slope - 1) \times X_c}{X_c}$ where the Intercept represents the constant bias at zero Sysmex
482 (reference method), Slope reflects the proportional bias, and X_c denotes the specific
483 Sysmex value for assessing percentage bias, the numerator combines the constant and
484 proportional biases and divide it by X_c to normalizes the bias; The red dashed line signifies
485 the zero bias, the blue dashed line represent $\pm 7\%$ acceptable difference, and the grey
486 shade indicates the 95% confidence interval.

487
488
489

1 **Comparison of haemoglobin concentration measurements using HemoCue-301 and**
2 **Sysmex XN-Series 1500: a survey among anaemic Gambian infants aged 6-12 months**

3

4 Mamadou Bah, MSc^{1,2}, Hans Verhoef, PhD², Abdou Camara¹, SEN, Morris Nden Ngom¹,
5 SEN, Demba Jallow¹, SEN, Kebba Bajo¹, Foday Bah¹, Maarten Pleij² BSc, Maaïke Klappe²
6 BSc, Alasana Saidykhan¹, BSc, Emmanuel Okoh, MBBS, MPH¹, Abdoulie Bah, BSc¹, Carla
7 Cerami, MD, PhD^{1*}

8 medRxiv preprint doi: <https://doi.org/10.1101/2024.09.05.24313093>; this version posted September 6, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

9 *¹Medical Research Council (MRC) Unit The Gambia at London School of Hygiene & Tropical
10 Medicine (LSHTM), PO Box 273, Fajara, The Gambia*


11 *²Division of Human Nutrition and Health, Wageningen University, PO Box 17, 6700 AA
12 Wageningen, The Netherlands*

13 **Correspondence to: Dr Carla Cerami at the MRC Unit The Gambia @ LSHTM, Atlantic
14 Boulevard, Fajara, Banjul, The Gambia Email: carla.cerami@lshtm.ac.uk; Tel: +220-
15 7875756*

16 **Table 1:** Presents the absolute and proportional bias with their corresponding 95%
17 confidence intervals, for haemoglobin concentration measurements obtained by
18 HemoCue-301. The absolute bias is expressed in grams per decilitre (g/dL), and the
19 proportional bias is presented as a percentage (%).

Aneamia Category	Sysmex Haemoglobin; g/dL	Absolute bias; g/dL (95% CI)	Proportional Bias; % (95% CI)
Severe	6.5	1.72 (1.37 to 2.10)	26.5 (21.1 to 32.3)
Moderate	8.0	1.12 (0.91 to 1.37)	14.0 (11.4 to 17.1)
Mild	10.0	0.32 (0.26 to 0.42)	3.2 (2.6 to 4.2)
normal	11.0	-0.08 (-0.18 to 0.07)	-7.3 (-6.5 to 0.6)

20



23 medRxiv preprint doi: <https://doi.org/10.1101/2024.09.05.24313093>; this version posted September 6, 2024. The copyright holder for this
 24 preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
 25 permanent form. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

26 HemoCue data were truncated at haemoglobin concentration <11.0g/dL (see text)

27 **Panel A:** The black line represents the Passing-Bablok equation: *HaemoCue Haemoglobin*
 28 $= \text{Intercept} (4.32) + \text{Slope}(0.60) \times \text{Sysmex Haemoglobin}$; the red dashed line
 29 represents the identity line; the grey shade area indicates the 95% confidence band.

30 **Panel B:** The black line represents the Passing-Bablok equation: *Absolute Bias* =
 31 $\text{HemoCue method} (\text{Intercept} + \text{Slope} \times \text{Sysmex Haemoglobin}) -$
 32 $(\text{Sysmex Haemoglobin}(\text{reference method}))$; the red line signifies the zero bias, the blue
 33 dashed line represent $\pm 7\%$ acceptable difference and the grey shade indicates the 95%
 34 confidence interval.

35 **Panel C:** The black line represents the Passing-Bablok equation: *Proportional bias*(X_c) =
 36 $\frac{\text{Intercept} + (\text{Slope} - 1) \times X_c}{X_c}$ where the Intercept represents the constant bias at zero Sysmex
 37 (reference method), Slope reflects the proportional bias, and X_c denotes the specific
 38 Sysmex value for assessing percentage bias, the numerator combines the constant and
 39 proportional biases and divide it by X_c to normalizes the bias; The red dashed line signifies
 40 the zero bias, the blue dashed line represent $\pm 7\%$ acceptable difference, and the grey
 41 shade indicates the 95% confidence interval.

42
43